AR049125A1 - Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. - Google Patents
Heterociclos biciclicos nitrogenados inhibidores de la aromatasa.Info
- Publication number
- AR049125A1 AR049125A1 ARP050102196A ARP050102196A AR049125A1 AR 049125 A1 AR049125 A1 AR 049125A1 AR P050102196 A ARP050102196 A AR P050102196A AR P050102196 A ARP050102196 A AR P050102196A AR 049125 A1 AR049125 A1 AR 049125A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxycarbonyl
- alkoxy
- aryl
- halogen
- Prior art date
Links
- 229910052757 nitrogen Inorganic materials 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 102000014654 Aromatase Human genes 0.000 title 1
- 108010078554 Aromatase Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000005103 alkyl silyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Heterociclos bicíclicos nitrogenados, proceso para su preparacion y uso de estos compuestos como medicamentos, en particular como inhibidores de la aromatasa. Reivindicacion 1: Compuestos de la formula general (1) o (1*) en el cual X es C; Y es C o N; Z es C; R a) es H; o b) es alquilo C1-8, alcoxi C1-8, halogeno o trifluorometilo; R1 es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, aril-alquilo C0-4 o heterociclilo-alquilo C0-4 no saturado, cuyos radicales se encuentran sustituidos o no por 1- 4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, aril-alcoxicarbonilo C0-4, arilo, ciano, halogeno, heterociclilo, oxo, trifluorometoxi, trifluorometilo o tri-alquilsililo C1-4; R2 a) es H; o b) es alquilo C1-8, cicloalquilo C3-8, halogeno, carboxi-alquilo C1-4, alcoxicarbonilo C1-4-alquilo C1-4, alquilcarbonilo C0-4, aril-alquilo C0-4 o heterociclil-alquilo C1-4 no saturado, cuyos radicales se encuentran sustituidos o no por 1-4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, aril-alcoxicarbonilo C0-4, arilo, ciano, halogeno, heterociclilo, oxo, trifluorometoxi, trifluorometilo o tri-alquilsililo C1-4; n es un numero 0, 1 o 2; * designa un átomo de C asimétrico y su sal, profármaco o compuesto en el cual uno o más átomos son reemplazados por sus isotopos estables no radioactivos, en particular sal apta para uso farmacéutico, en el cual, si X Y y Z son C, R1 no es un radical bencilo no sustituido o sustituido por alcoxi; o si R es metilo, R1 difiere de metilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH9152004 | 2004-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049125A1 true AR049125A1 (es) | 2006-06-28 |
Family
ID=34968588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102196A AR049125A1 (es) | 2004-05-28 | 2005-05-27 | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. |
| ARP050102199A AR049126A1 (es) | 2004-05-28 | 2005-05-27 | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102199A AR049126A1 (es) | 2004-05-28 | 2005-05-27 | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8680079B2 (es) |
| EP (2) | EP1765777A2 (es) |
| JP (2) | JP5179174B2 (es) |
| CN (2) | CN1968930A (es) |
| AR (2) | AR049125A1 (es) |
| BR (2) | BRPI0510409A (es) |
| CA (2) | CA2568159A1 (es) |
| IL (2) | IL179408A0 (es) |
| TW (2) | TW200616623A (es) |
| WO (2) | WO2005118540A2 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680079B2 (en) | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
| WO2006005725A2 (en) * | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | N containing condensed heterocycles with antitumor effects |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| AR060225A1 (es) * | 2006-03-31 | 2008-06-04 | Speedel Experimenta Ag | Proceso para preparar 6,7- dihidro-5h-imidazo (1,5-a) piridin -8- ona |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200813071A (en) | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| MX2011000023A (es) * | 2008-07-24 | 2011-03-30 | Meiji Seika Kaisha | Gen biosintetico de piripiropeno a. |
| US9216221B2 (en) | 2008-11-07 | 2015-12-22 | University Of Sheffield | Medicament and method of diagnosis for treating subclinical Cushing's syndrome |
| US8853413B2 (en) | 2009-05-13 | 2014-10-07 | Meiji Seika Pharma Co., Ltd. | Process for producing pyripyropene derivatives |
| MX2011012628A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. |
| MA33364B1 (fr) | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
| EP2993169B1 (en) * | 2009-11-17 | 2017-12-20 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| UA111151C2 (uk) | 2010-03-01 | 2016-04-11 | Мейдзі Сейка Фарма Ко., Лтд. | Спосіб одержання похідних пірипіропену |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| CN103958478B (zh) * | 2011-11-30 | 2017-08-01 | 霍夫曼-拉罗奇有限公司 | 双环二氢异喹啉‑1‑酮衍生物 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| HRP20180958T1 (hr) | 2013-02-14 | 2018-07-27 | Novartis Ag | Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu) |
| EA201690278A1 (ru) | 2013-07-25 | 2016-06-30 | Новартис Аг | Циклические полипептиды для лечения сердечной недостаточности |
| JP2016527249A (ja) | 2013-07-25 | 2016-09-08 | ノバルティス アーゲー | 合成アペリンポリペプチドのバイオコンジュゲート |
| CN105593212B (zh) * | 2013-10-17 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物 |
| RU2016116433A (ru) * | 2013-10-17 | 2017-11-22 | Ф. Хоффманн-Ля Рош Аг | Новые производные фенил-дигидропиридина в качестве ингибиторов альдостерон синтазы |
| RU2016116435A (ru) | 2013-10-17 | 2017-11-22 | Ф. Хоффманн-Ля Рош Аг | Производные фенил-дигидропиридина в качестве ингибиторов альдостеронсинтазы |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| AU2018230521B2 (en) | 2017-03-10 | 2022-02-03 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| EP3887388A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
| CN117659075B (zh) * | 2023-12-18 | 2025-02-11 | 中国科学院兰州化学物理研究所 | 一种咪唑衍生型柱[5]芳烃手性填料的制备及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| JPH0670064B2 (ja) | 1986-12-08 | 1994-09-07 | 三井石油化学工業株式会社 | 二環性イミダゾ−ル誘導体 |
| GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
| US5057521A (en) | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
| PT625155E (pt) * | 1992-01-27 | 2002-01-30 | Janssen Pharmaceutica Nv | Derivados de 1h-benzimidazol substituidos por pirrolo-imidazolilo e imidazopiridinilo utilizados como inibidores de aromatase |
| US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| WO1997000257A1 (en) * | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| US6333335B1 (en) * | 1999-07-23 | 2001-12-25 | Merck & Co., Inc. | Phenyl-protein transferase inhibitors |
| JP2001151696A (ja) * | 1999-11-22 | 2001-06-05 | Keiko Tanaka | アクチニジンから造る腫瘍の増殖ならびに転移抑制酵素と異質なたんぱく細胞の除去剤 |
| US7141598B2 (en) * | 2000-11-17 | 2006-11-28 | Takeda Pharmaceutical Company, Ltd. | Imidazole derivatives, production method thereof and use thereof |
| DE602005025110D1 (de) | 2004-05-28 | 2011-01-13 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
| AR049388A1 (es) | 2004-05-28 | 2006-07-26 | Speedel Experimenta Ag | Heterociclos como inhibidores de aldosterona sintasa |
| US8680079B2 (en) * | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200813071A (en) | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
-
2005
- 2005-05-27 US US11/597,623 patent/US8680079B2/en not_active Expired - Fee Related
- 2005-05-27 EP EP05747969A patent/EP1765777A2/en not_active Withdrawn
- 2005-05-27 BR BRPI0510409-2A patent/BRPI0510409A/pt not_active IP Right Cessation
- 2005-05-27 EP EP05752767A patent/EP1749005A1/en not_active Withdrawn
- 2005-05-27 US US11/597,585 patent/US20080076784A1/en not_active Abandoned
- 2005-05-27 JP JP2007513942A patent/JP5179174B2/ja not_active Expired - Fee Related
- 2005-05-27 CN CNA2005800170603A patent/CN1968930A/zh active Pending
- 2005-05-27 CA CA002568159A patent/CA2568159A1/en not_active Abandoned
- 2005-05-27 CN CNA2005800173175A patent/CN1960991A/zh active Pending
- 2005-05-27 BR BRPI0511621-0A patent/BRPI0511621A/pt not_active IP Right Cessation
- 2005-05-27 WO PCT/EP2005/052416 patent/WO2005118540A2/en not_active Ceased
- 2005-05-27 CA CA002568163A patent/CA2568163A1/en not_active Abandoned
- 2005-05-27 AR ARP050102196A patent/AR049125A1/es unknown
- 2005-05-27 TW TW094117480A patent/TW200616623A/zh unknown
- 2005-05-27 TW TW094117477A patent/TW200612947A/zh unknown
- 2005-05-27 AR ARP050102199A patent/AR049126A1/es unknown
- 2005-05-27 JP JP2007513939A patent/JP2008500997A/ja active Pending
- 2005-05-27 WO PCT/EP2005/052419 patent/WO2005118581A1/en not_active Ceased
-
2006
- 2006-11-20 IL IL179408A patent/IL179408A0/en unknown
- 2006-11-20 IL IL179406A patent/IL179406A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL179406A0 (en) | 2007-05-15 |
| JP5179174B2 (ja) | 2013-04-10 |
| JP2008500997A (ja) | 2008-01-17 |
| TW200616623A (en) | 2006-06-01 |
| BRPI0510409A (pt) | 2007-10-23 |
| US20070225232A1 (en) | 2007-09-27 |
| AR049126A1 (es) | 2006-06-28 |
| IL179408A0 (en) | 2007-05-15 |
| CN1968930A (zh) | 2007-05-23 |
| EP1765777A2 (en) | 2007-03-28 |
| WO2005118540A3 (en) | 2006-02-02 |
| WO2005118540A2 (en) | 2005-12-15 |
| CA2568159A1 (en) | 2005-12-15 |
| EP1749005A1 (en) | 2007-02-07 |
| WO2005118581A1 (en) | 2005-12-15 |
| CA2568163A1 (en) | 2005-12-15 |
| CN1960991A (zh) | 2007-05-09 |
| US20080076784A1 (en) | 2008-03-27 |
| TW200612947A (en) | 2006-05-01 |
| JP2008501000A (ja) | 2008-01-17 |
| BRPI0511621A (pt) | 2008-01-02 |
| US8680079B2 (en) | 2014-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| BRPI0810929B8 (pt) | uso de um composto de fórmula 1 | |
| AR058005A1 (es) | Derivados fluorados de 4-(2- amino-1-hidroxietil) fenol como agonistas del receptor beta 2 adrenergico | |
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
| AR076838A1 (es) | Sulfonamidas nematocidas | |
| CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| PE20071286A1 (es) | Composicion para inducir tolerancia viral en plantas | |
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |